KLRC1 and rheumatoid arthritis: Currently, using monalizumab (namely, NKG2A monoclonal antibody), in rheumatoid arthritis (RA) and several neoplastic disorders might be an efficient target as a new anti-SARS-CoV-2 strategy that potentially reverses the inhibition of the innate immune system induced by the virus and leads to improved NK cells cytotoxicity at the early stage of the disease.